Bryan, Garnier & Co Initiates Coverage on Travere Therapeutics (NASDAQ:TVTX)

Bryan, Garnier & Co started coverage on shares of Travere Therapeutics (NASDAQ:TVTXGet Rating) in a report issued on Wednesday morning, MarketBeat reports. The brokerage issued a sell rating and a $17.00 target price on the stock.

Several other brokerages have also recently weighed in on TVTX. Barclays lowered their price target on shares of Travere Therapeutics to $37.00 in a research report on Tuesday, August 9th. Evercore ISI decreased their target price on shares of Travere Therapeutics to $35.00 in a research report on Tuesday, August 9th. Piper Sandler decreased their target price on shares of Travere Therapeutics from $41.00 to $39.00 in a research report on Monday, August 15th. SVB Leerink increased their target price on shares of Travere Therapeutics from $42.00 to $45.00 and gave the company an outperform rating in a research report on Friday, August 5th. Finally, Canaccord Genuity Group reissued a buy rating and set a $42.00 target price on shares of Travere Therapeutics in a research report on Thursday, July 14th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, Travere Therapeutics has an average rating of Moderate Buy and an average price target of $36.71.

Travere Therapeutics Price Performance

Shares of TVTX opened at $24.90 on Wednesday. The company has a 50 day moving average price of $26.18 and a 200-day moving average price of $25.48. Travere Therapeutics has a fifty-two week low of $20.80 and a fifty-two week high of $31.65. The stock has a market capitalization of $1.58 billion, a PE ratio of -6.77 and a beta of 0.58. The company has a debt-to-equity ratio of 2.39, a quick ratio of 4.65 and a current ratio of 4.71.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TVTX. Deep Track Capital LP acquired a new position in Travere Therapeutics during the 4th quarter valued at approximately $76,048,000. Lynx1 Capital Management LP acquired a new stake in shares of Travere Therapeutics in the fourth quarter worth $22,878,000. Kynam Capital Management LP increased its stake in shares of Travere Therapeutics by 378.3% in the first quarter. Kynam Capital Management LP now owns 870,918 shares of the company’s stock worth $22,444,000 after acquiring an additional 688,815 shares during the period. State Street Corp increased its stake in shares of Travere Therapeutics by 21.9% in the second quarter. State Street Corp now owns 3,607,165 shares of the company’s stock worth $87,402,000 after acquiring an additional 647,804 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Travere Therapeutics by 205.3% in the second quarter. Assenagon Asset Management S.A. now owns 950,465 shares of the company’s stock worth $23,030,000 after acquiring an additional 639,114 shares during the period.

About Travere Therapeutics

(Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Read More

Analyst Recommendations for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.